Health Care [ 10/12 ] | Biotechnology [ 38/73 ]
NASDAQ | Common Stock
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 31, 25 | -1.28 Decreased by -2.40% | -0.69 Decreased by -85.51% |
| Jul 22, 25 | -9.48 Increased by +28.99% | -2.70 Decreased by -251.11% |
| Mar 10, 25 | -1.71 Decreased by -350.00% | -3.19 Increased by +46.39% |
| Dec 11, 24 | -3.60 Decreased by -718.18% | -3.42 Decreased by -5.26% |
| Sep 11, 24 | -1.25 Decreased by -3.02 K% | -2.38 Increased by +47.48% |
| Jul 27, 24 | -13.35 Decreased by -44.40 K% | -2.75 Decreased by -385.45% |
| Mar 25, 24 | -0.38 Decreased by -533.33% | -0.32 Decreased by -18.75% |
| Dec 15, 23 | -0.44 Decreased by -1.37 K% | -0.67 Increased by +34.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jul 31, 25 | N/A Decreased by N/A% | -2.70 M Decreased by -177.48% | - - |
| Apr 30, 25 | 0.00 Decreased by -100.00% | -1.14 M Decreased by -33.81% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 25 | 0.00 Decreased by N/A% | -1.04 M Increased by +60.97% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 24 | 0.00 Decreased by N/A% | -1.36 M Increased by +53.13% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 24 | 0.00 Decreased by N/A% | -974.00 K Increased by +72.39% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 24 | 76.11 K Increased by +N/A% | -851.53 K Increased by +74.24% | Decreased by -1.12 K% Decreased by N/A% |
| Jan 31, 24 | 0.00 Decreased by N/A% | -2.66 M Increased by +50.94% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 23 | 0.00 Decreased by N/A% | -2.91 M Increased by +6.67% | Decreased by N/A% Decreased by N/A% |